Evidence map›Paper›PMID 41443868›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Anti-programmed Death-ligand 1 Antibody-associated Eosinophilic Granulomatosis with Polyangiitis in Non-small Cell Lung Cancer.

Akira Sugimoto, Hiroyasu Kaneda, Satoshi Nozuchi, Toshikazu Mino, Itsuki Hasegawa, Megumi Mizutani, Hiroaki Nagamine, Yoshiya Matsumoto, Takako Oka, Yoko Tani and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Akira SugimotoDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Hiroyasu KanedaDepartment of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Satoshi NozuchiDepartment of Neurology, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Toshikazu MinoDepartment of Neurology, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Itsuki HasegawaDepartment of Neurology, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Megumi MizutaniDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Hiroaki NagamineDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Yoshiya MatsumotoDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Takako OkaDepartment of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Yoko TaniDepartment of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Kazuhiro YamadaDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Tetsuya WatanabeDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Kazuhisa AsaiDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Yoshiaki ItohDepartment of Neurology, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Tomoya KawaguchiDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA), a subtype of antineutrophil cytoplasmic antibody (ANCA)-related vasculitis, is rarely reported as an immune-related adverse event. We herein present the case of a 61-year-old woman with non-small cell lung cancer treated with durvalumab after definitive chemoradiotherapy. Following durvalumab treatment initiation, she experienced numbness in her hands and feet, and drop foot in her right ankle. She was subsequently diagnosed with peripheral neuropathy, eosinophilia, and myeloperoxidase-ANCA positivity, and had a history of asthma. Consequently, the patient was diagnosed as having EGPA. We report the first case of EGPA caused by durvalumab, an anti-programmed death-ligand 1 (PD-L1) antibody.

Indexed as

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalB7-H1 AntigenCarcinoma, Non-Small-Cell LungChurg-Strauss SyndromeGranulomatosis with PolyangiitisLung NeoplasmsFemaleHumansMiddle AgedAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humandurvalumabanti-programmed death-ligand 1 (PD-L1) antibodycase reporteosinophilic granulomatosis with polyangiitis (EGPA)immune-related adverse event (irAE)neuropathy

Identifiers

PMID41443868
PMCPMC13561571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.